CellRep Information

CellRep develops AI-discovered small molecules that reprogram T cells during ex vivo manufacturing, steering them toward a stem-like, exhaustion-resistant state. The compound is added to the culture, washes out before infusion, and the reprogrammed state persists. What reaches the patient is the same CAR-T product, built from better cells. Our premise is that T cell exhaustion is a software problem. Cells are computational systems, and their state can be rewritten with transient chemical signals rather than permanent genetic edits. This is the same logic behind partial reprogramming in longevity research, applied to the cells that fight cancer. The platform integrates in silico target discovery, in vitro validation and in vivo testing. Our lead program has shown a 6.6x increase in T cell polyfunctionality (52.8% vs 8% baseline), a 50 to 60% rise in TCF-1, and roughly 2x antitumor capacity in a MUC1 triple-negative breast cancer model. Four patent filings cover novel targets (including Nur77 and IKZF), de novo chemical scaffolds and the AI platform. Because the molecules act as manufacturing reagents and leave the final product, they can be incorporated into existing CAR-T programs as a CMC modification, without a separate IND. That is our path to the clinic: partnering with cell therapy centers, starting with Baylor College of Medicine, to improve the products they already make. CellRep is a Delaware company with teams in Houston, Bogotá and Buenos Aires. Cancer is the beachhead. The same chemistry opens chronic viral infections and, further out, longevity medicine.